...
首页> 外文期刊>Clinical Interventions in Aging >Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients
【24h】

Cost-effectiveness analysis of oral versus intravenous drip infusion of levofloxacin in the treatment of acute lower respiratory tract infection in Chinese elderly patients

机译:左氧氟沙星口服滴注与静脉滴注治疗中国老年急性下呼吸道感染的成本效益分析

获取原文
           

摘要

Aim: Pharmacoeconomic cost-effectiveness analysis of two different dosage regimens of levofloxacin in the treatment of acute lower respiratory tract infection in elderly patients. Methods: A total of 108 elderly patients with acute lower respiratory tract infection who visited by our hospital between September 2013 and September 2014 were randomly divided into Group A and Group B, with 54 patients in each group. In Group A, levofloxacin injection was given for continuous intravenous infusion treatment, whereas in Group B, levofloxacin injection and levofloxacin capsule were given as sequential therapy (ST). The period of treatment for both the groups was 10 days, and minimum cost analysis was used to analyze the treatment. Results: Groups A and B had cure rates of 61.1% and 59.3% ( P >0.05), effective rates of 88.9% and 83.3% ( P >0.05), bacterial clearance rates of 96.3% and 92.6% ( P >0.05), and incidence rates of adverse reactions of 7.4% and 3.7% ( P >0.05), respectively. Treatment costs of Groups?A and B were 1,588 RMB and 1,150 RMB, respectively, whereas the cost-effectiveness of the two groups was at 17.86 and 13.81, respectively ( P <0.05). Conclusion: Levofloxacin ST had relatively higher cost-effectiveness ratio for the treatment of acute lower respiratory tract infection in elderly patients, especially Chinese.
机译:目的:左氧氟沙星两种不同剂量方案治疗老年患者急性下呼吸道感染的药效经济性分析。方法:将2013年9月至2014年9月期间我院就诊的108例老年急性下呼吸道感染患者随机分为A组和B组,每组54例。 A组给予左氧氟沙星注射液进行连续静脉输注治疗,而B组则给予左氧氟沙星注射液和左氧氟沙星胶囊作为序贯治疗(ST)。两组的治疗时间均为10天,并使用最小费用分析法对治疗进行了分析。结果:A,B组治愈率分别为61.1%和59.3%(P> 0.05),有效率为88.9%和83.3%(P> 0.05),细菌清除率分别为96.3%和92.6%(P> 0.05),不良反应发生率分别为7.4%和3.7%(P> 0.05)。 A组和B组的治疗费用分别为1588元和1150元,而两组的成本效益分别为17.86元和13.81元(P <0.05)。结论:左氧氟沙星ST治疗老年患者尤其是中国人的急性下呼吸道感染具有较高的成本效益比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号